Who Paid My Doc
Tiffany Owens
Allergy Columbus, OH Medical Doctor
NPI 1508962242 CMS profile 719704
915 Olentangy River Rd Fl 4, Columbus, OH 43212
General payments
$116
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Tiffany Owens of Columbus, OH is reported in the CMS Open Payments database as having received $116 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 13th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $116 | 1 |
Beside peers
- Tiffany Owens
- Allergy median
- Middle half of Allergy
- National median
In program year 2025, general payments to Tiffany Owens were reported at $116. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.
Show as a table
| Year | Tiffany Owens | Allergy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $506 | $151–$1,337 | $163 |
| 2020 | $0 | $409 | $108–$1,162 | $114 |
| 2021 | $0 | $549 | $125–$1,485 | $132 |
| 2022 | $0 | $666 | $161–$1,594 | $149 |
| 2023 | $0 | $780 | $186–$1,916 | $160 |
| 2024 | $0 | $1,031 | $271–$2,196 | $164 |
| 2025 | $116 | $1,143 | $226–$2,504 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
393
Drug cost
$237,664
Branded share of claims
26.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | Brand | 35 | $165,857 | |
| Dupixent Syringe Dupilumab | Brand | 14 | $51,143 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 11 | $8,283 | |
| Dulera Mometasone/Formoterol | Brand | 12 | $3,914 | |
| Epinephrine | Generic | 21 | $2,975 | |
| Azelastine Hcl | Generic | 88 | $2,022 | |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | Brand | 14 | $1,484 | |
| Montelukast Sodium | Generic | 71 | $495 | |
| Ipratropium Bromide | Generic | 20 | $409 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 19 | $330 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 20 billing codesPaid by Medicare
$13,768
Medicare patients
100
Services billed
837
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 58% | |
| Arthritis | 54% | |
| Depression | 35% | |
| Osteoporosis | 28% | |
| Ischemic heart disease | 25% | |
| Diabetes | 24% | |
| COPD | 22% | |
| Chronic kidney disease | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy in Ohio
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.